期刊
DRUG DESIGN DEVELOPMENT AND THERAPY
卷 7, 期 -, 页码 167-174出版社
DOVE MEDICAL PRESS LTD
DOI: 10.2147/DDDT.S31500
关键词
prostate cancer; castration resistant prostate cancer; antiangiogenesis; S100A9; HDAC4; ABR-215050; quinoline-3-carboximide
资金
- Cancer Research UK [12173] Funding Source: researchfish
Castration resistant prostate cancer remains a major clinical burden and novel-therapeutic options are urgently required to improve survival. Tasquinimod is an orally-administered quinoline-3-carboxamide with potent antiangiogenic and antitumorigenic action that has shown promise in the treatment of advanced prostate cancers. This review explores both preclinical and clinical findings to date. In summary, tasquinimod has been shown to demonstrate a potent in vitro and in vivo anticancer action and completed early phase clinical trials have demonstrated good drug tolerance and prolonged progression-free survival. Although Phase III clinical trials are on-going, the findings to date highlight the promise of this drug in the treatment of advanced prostate cancer.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据